An efficacious COVID-19 vaccine is currently the world's leading research priority. Several
nations have indicated that if there is a compelling case for use of a vaccine before it is …

Large-scale deployment of COVID-19 vaccines will seriously affect the ongoing phases 2
and 3 randomised placebo-controlled trials assessing SARS-CoV-2 vaccine candidates …

ABSTRACT Introduction The coronavirus 19 (COVID-19) pandemic triggered a
simultaneous global demand for preventative vaccines, which quickly became a high priority …

Emergency Use Authorization of Covid Vaccines A median 2-month follow-up after
completion of an investigational Covid-19 vaccine regimen is necessary to provide safety …

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has caused more than 1 million deaths in the first 6 months of the pandemic and huge …

Background The rapid process of research and development and lack of follow-up time post-
vaccination aroused great public concern about the safety profile of COVID-19 vaccine …

Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …

Three issues are crucial in planning COVID19 vaccine trials:(1) whether to demand not only
proof of some vaccine efficacy but also proof of worthwhile efficacy;(2) whether the initial …

On Feb 24, 2021, 600 000 doses of the Oxford–AstraZeneca COVID-19 vaccine arrived in
Ghana. 2 days later, 500 000 doses of the same vaccine landed in the Ivory Coast. The west …

Since its emergence in December 2019, SARS-CoV-2, the virus that causes coronavirus
disease 2019 (COVID-19), has taken a tremendous toll globally; by 28 February 2021, there …